208 related articles for article (PubMed ID: 11012558)
21. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
Jagannathan V; Venitz J
Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
[TBL] [Abstract][Full Text] [Related]
22. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.
Gajjar DA; Bello A; Ge Z; Christopher L; Grasela DM
Antimicrob Agents Chemother; 2003 Jul; 47(7):2256-63. PubMed ID: 12821477
[TBL] [Abstract][Full Text] [Related]
23. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
24. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain.
Bellemère G; Vaudry H; Morain P; Jégou S
J Neuroendocrinol; 2005 May; 17(5):306-13. PubMed ID: 15869566
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
Quartino A; Huledal G; Sparve E; Lüttgen M; Bueters T; Karlsson P; Olsson T; Paraskos J; Maltby J; Claeson-Bohnstedt K; Lee CM; Alexander R; Fälting J; Paulsson B
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):396-405. PubMed ID: 27129013
[TBL] [Abstract][Full Text] [Related]
27. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry.
Arnold O; Saletu B; Anderer P; Assandri A; di Padova C; Corrado M; Saletu-Zyhlarz GM
Eur Neuropsychopharmacol; 2005 Oct; 15(5):533-43. PubMed ID: 16046102
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and safety of Z-321, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
Umemura K; Kondo K; Ikeda Y; Nishimoto M; Hiraga Y; Yoshida Y; Nakashima M
J Clin Pharmacol; 1999 May; 39(5):462-70. PubMed ID: 10234593
[TBL] [Abstract][Full Text] [Related]
31. Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys.
Schneider JS; Giardiniere M; Morain P
Neuropsychopharmacology; 2002 Feb; 26(2):176-82. PubMed ID: 11790513
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Uematsu T; Kanamaru M; Kosuge K; Hara K; Uchiyama N; Takenaga N; Tanaka W; Friedman BS; Nakashima M
Br J Clin Pharmacol; 1995 Jul; 40(1):59-66. PubMed ID: 8527269
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.
Liao WC; Vesterqvist O; Delaney C; Jemal M; Ferreira I; Ford N; Swanson B; Uderman H
Br J Clin Pharmacol; 2003 Oct; 56(4):395-406. PubMed ID: 12968984
[TBL] [Abstract][Full Text] [Related]
34. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.
Qiu R; Ahn JE; Alexander R; Brodney MA; He P; Leurent C; Mancuso J; Margolin RA; Tankisheva E; Chen D
J Alzheimers Dis; 2019; 71(2):581-595. PubMed ID: 31424395
[TBL] [Abstract][Full Text] [Related]
35. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients.
Stangier J; Su CA; Roth W
J Int Med Res; 2000; 28(4):149-67. PubMed ID: 11014323
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
40. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
